Phase 2TerminatedINTERVENTIONAL
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
ClinicalTrials.gov · NCT01886287 · Registry updated: 2015-01-12
- Condition / research focus
- Neuroendocrine Carcinoma
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2013-12. Completion: 2014-10 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Octreotide LAR (drug) — also listed as: Sandostatin LAR®
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Site recruitment: Not reported